Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin's lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibody

Clinical Lymphoma

Volumn 4, Issue 1, 2003, Pages 56-59

  Tsai, Donald E ^a   Maillard, Ivan ^a   Schuster, Stephen J ^a   Nasta, Sunita D ^a   Porter, David L ^a   Klumpp, Thomas R ^a   Goldenberg, David M ^b   Luger, Selina M ^a   Alavi, Abass ^a   Sharkey, Robert M ^b   Hartzell, Kenneth B ^a   Stadtmauer, Edward A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b GARDEN STATE CANCER CENTER   (United States)

Author keywords

Bone marrow; CHOP; Epratuzumab; Non Hodgkin's lymphoma; Radiation therapy

Indexed keywords

ADENOSINE DERIVATIVE; CD20 ANTIGEN; CD22 ANTIGEN; CHLORAMBUCIL; CHLORODEOXYADENOSINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPRATUZUMAB; IBRITUMOMAB TIUXETAN; MONOCLONAL ANTIBODY; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE; YTTRIUM 90;

ADULT; ARTICLE; B CELL LYMPHOMA; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; CASE REPORT; DRUG RESPONSE; DRUG TOLERABILITY; HUMAN; ISOTOPE LABELING; MALE; NONHODGKIN LYMPHOMA; PANCYTOPENIA; RADIOIMMUNOTHERAPY; RELAPSE;

EID: 0038692108     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2003.n.015     Document Type: Article

References (21)

1. Zelenetz AD. Radioimmunotherapy for lymphoma. Curr Opin Oncol 1999; 11:375-380.
2. Goldenberg DM. The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy. Crit Rev Oncol Hematol 2001; 39:195-201.
3. Witzig TE, White CA, Wiseman G, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999; 17:3793-3803.
4. Knox SJ, Goris ML, Trisler K, et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 1996; 2:457-470.
5. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20:2453-2463.
6. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002; 20:3262-3269.
7. Wiseman G, Gordon LI, Multani PS, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter study. Blood 2002; 99:4336-4342.
8. Johnson PW, Rohatiner AZ, Whelan JS. Patterns of survival in paients with recurrent follicular lymphoma: a 20-year study from a single institution. J Clin Oncol 1995; 13:140-147.
9. Horning S, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 1984; 311:1471-1475.
10. McKelvey EM, Gottlieb JA, Wilson HE, et al. Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976; 38:1484-1493.
11. McLaughlin P, Grillo-Lopez AJ, Link BK. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16:2825-2833.
12. Goldenberg DM, Horowitz JA, Sharkey RM, et al. Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody. J Clin Oncol 1991; 9:548-564.
13. Hajjar G, Burton J, Sharkey RM, et al. Phase I/II radioimmunotherapy trial with 90Y-labeled epratuzumab in relapsed refractory non-Hodgkin's lymphoma. J Nucl Med 2001; 42:157.
14. Tsai DE, Schuster SJ, Matthies A, et al. Progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem-cell transplantation: changing the natural history with monoclonal antibody therapy. Clin Lymphoma 2000; 1:62-66.
15. Shih LB, Luhh Z, Xaun H, et al. Internalization and intracellular processing of an anti-B cell lymphoma monoclonal antibody LL2. Int J Cancer 1994; 56:538-545.
16. Leung SO, Goldenberg DM, Dion AS, et al. Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific leukemia/lymphoma antibody, LL2. Mol Immunol 1995; 32:1413-1427.
17. Griffiths GL, Govindan SV, Sharkey RM, et al. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma. J Nucl Med 2003; 44:77-84.
18. Juweid ME, Stadtmauer EA, Hajjar G, et al. Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labelled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma. Clin Cancer Res 1999; 5(suppl 10):3292s-3303s.
19. Vose JM, Wahl RL, Saleh MN, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphoma. J Clin Oncol 2000; 18:1316-1323.
20. Emami B, Lyman J, Brown A. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991; 21:109-122.
21. Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin's lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000; 96:1259-1266.